DC/CIK治疗对肺癌患者肝脏和肾脏的影响及护理干预  

The impact and nursing intervention of DC/CIK cell therapy on the liver and renal in patients with lung cancer

作　　者：文娟[1] 安东建[1] 

机构地区：[1]长沙市中心医院肿瘤科,湖南长沙410004

出　　处：《中国当代医药》2013年第20期148-149,151,共3页China Modern Medicine

基　　金：吴阶平医学基金会临床科研专项资助基金(320.6799.1096)

摘　　要：目的探讨树突状细胞/细胞因子诱导的杀伤细胞(DC/CIK)治疗对肝脏和肾脏的影响及护理干预。方法回顾性分析63例接受DC/CIK细胞治疗和同期接受化疗的70例晚期肺癌患者的临床资料。结果 DC/CIK细胞治疗组有3例肝功能异常,发生率为4.7%,4例肾功能异常,发生率为6.3%;化疗组有14例肝功能异常,发生率为20.0%,16例肾功能异常,发生率为22.8%。两组相比,差异有统计学意义(P<0.01)。结论与化疗相比,DC/CIK细胞治疗对肺癌患者的肝肾功能影响轻微,如早期给予护理干预,临床应用安全可靠。Objective To explore the impact and nursing intervention of the DC/CIK cell therapy on the liver and kidney in patients with lung cancer. Methods A retrospective liver and kidney function date analysis of 63 cases of lung cancer patients receiving DC/CIK cell therapy was done. At the same time, A retrospective liver and kidney function date analysis of 70 cases of lung cancer patients receiving chemotherapy was done. Results In the 63 patients receiving DC/CIK cell therapy, there were 3 cases of abnormal liver function and 4 cases of kidney dysfunction, the in- cidence rate is 4.7% and 6.3% respectively. There were 14 cases of abnormal liver function and 16 cases of renal dys- function in the 70 patients receiving chemotherapy, the incidence rate was 20.0% and 22.8% respectively. The differ- ence between two groups was significant （/9 〈 0.01）. Conclusion Compared with chemotherapy, the liver and kidney in patients with lung cancer are affected mildly by DC/CIK cell therapy. Taking early nursing intervention, clinical use of DC/CIK cell therapy is safe.

关 键 词：DC CIK细胞 肺癌 肝脏 肾脏 护理干预 

分 类 号：R734.2[医药卫生—肿瘤]